ALT Stock Analysis

Understanding Altimmune Inc (ALT): A Comprehensive StockValueFinder Educational Review

This research article provides a detailed educational analysis of Altimmune Inc (ALT), operating within the healthcare sector and specifically the biotechnology industry. This report is a complete StockValueFinder review designed to teach investors how to interpret specific financial metrics and understand the underlying mechanics of stock valuation and risk assessment. This is not a recommendation to trade; rather, it is an exercise in applying quantitative filters to evaluate the financial health and market positioning of a specific ticker.

Overview of Altimmune Inc (ALT)

Altimmune Inc (ALT) is a biotechnology company. In the biotechnology sector, companies often face unique financial profiles characterized by high research and development costs, significant capital requirements, and varying stages of product development. Because many biotech firms are pre-revenue or in the clinical trial phase, their financial statements often look very different from established industrial or consumer goods companies.

As of the most recent data used for this analysis, Altimmune Inc is trading at a price of $2.17. When evaluating a stock like ALT, an investor must look beyond the share price and examine the fundamental health of the business through various lenses: profitability, capital efficiency, debt management, and valuation.

Why the StockValueFinder Score Matters

The StockValueFinder score is a proprietary quantitative aggregate used to provide a snapshot of a company's fundamental strength based on specific, pre-defined financial tests. For Altimmune Inc, the current score is 33%.

In our grading system, a higher score indicates that a company has successfully passed more of the critical financial hurdles related to profitability, debt safety, and valuation. A score of 33% is considered low, resulting in a rating of **AVOID**. This rating does not predict future price movements; instead, it reflects that the company currently fails to meet the rigorous quantitative standards required for a high-quality fundamental profile. For an investor, understanding this score is about recognizing that the company lacks the mathematical "safety net" typically found in higher-scoring stocks.

EPS Strength and Consistency

Earnings Per Share (EPS) is a fundamental metric used to determine how much profit a company generates for each outstanding share of common stock. Consistency in EPS is vital because it demonstrates a company's ability to generate repeatable value for its shareholders.

In the case of Altimmune Inc, the system recorded a result of **"Did not pass"** for the EPS test. While specific historical EPS values were not supplied in this data set, a "fail" indicates that the company is not meeting the required threshold for earnings stability or profitability.

**Educational Example:** To evaluate other stocks, consider the concept of consistency. Imagine Company A has an EPS that grows steadily from $1.00 to $1.20 over three years, while Company B has an EPS that swings wildly from +$2.00 to -$1.50. Even if Company B has a higher peak, Company A is generally considered to have higher "EPS strength" because its earnings are predictable. When a company fails the EPS test, it suggests that the business may be experiencing volatility or losses that could threaten its long-term stability.

ROIC and Capital Efficiency

Return on Invested Capital (ROIC) is one of the most critical metrics for assessing how effectively a company uses its money to generate more profit. It measures the return a company generates on all the capital (both debt and equity) it has deployed in its operations.

Altimmune Inc reports an ROIC of **-33.81%**.

In professional fundamental analysis, a strong or attractive ROIC is generally considered to be 10% or higher. A high ROIC suggests a "moat" or a competitive advantage that allows the company to turn capital into significant profit. Conversely, a weak or negative ROIC indicates that the company is destroying value rather than creating it; for every dollar invested into the business, the company is losing capital.

**Educational Example:** Think of ROIC like a machine. If you put $100 into a machine (capital) and it gives you back $15, that is a 15% ROIC. This is considered efficient. If you put $100 into a machine and it gives you back only $4, that is a 4% ROIC, which may not even cover the cost of the capital used. If you put $100 into a machine and it gives you back -$33.81 (as in the case of ALT), you are losing a significant portion of your investment through the operation itself.

Interest Coverage and Financial Safety

Interest coverage is a solvency ratio that measures how easily a company can pay the interest expenses on its outstanding debt. This is a crucial metric for assessing "purchasing-power risk" and the threat of insolvency during periods of high interest rates or economic contraction.

The StockValueFinder system recorded that Altimmune Inc **"Did not pass"** the interest coverage test.

A healthy or strong interest coverage ratio is typically 6 or higher. This provides a cushion; if earnings drop, the company still has plenty of cash flow to satisfy its lenders. A weak or risky range is often considered to be below 2, where a small dip in earnings could make it impossible for the company to meet its interest obligations.

**Educational Example:** Imagine a person has $1,000 in monthly income and owes $500 in interest on a loan. Their coverage is 2x ($1,000 / $500). This is risky; if their income drops to $600, they can no longer pay the interest. Now imagine a person has $1,000 in income and only owes $100 in interest. Their coverage is 10x ($1,000 / $100). This person is in a much safer position to weather financial storms.

Debt Payback and Balance Sheet Discipline

Debt payback (often expressed as the number of years required to pay off total debt) measures how long it would take a company to clear its liabilities if it used all its available cash flow.

Altimmune Inc has a debt payback value of **-0.51 years**.

StockValueFinder prefers a debt payback of 3 years or less. A lower number indicates a more disciplined balance sheet and less long-term debt risk. While the negative number here is mathematically unusual (often occurring in specific accounting treatments of cash vs. debt), the system marked this test as **PASSED**. Generally, a company that can clear its debts in 1.5 years is much more attractive than one that requires 7 years, as the shorter timeframe reduces exposure to rising interest rates and currency instability.

**Educational Example:** If a company has $1 million in debt and generates $500,000 in annual cash flow, its debt payback is 2 years. This is considered efficient and disciplined. If the company only generates $100,000 a year, its payback is 10 years, which represents significantly higher long-term uncertainty.

P/E Ratio and Valuation Discipline

The Price-to-Earnings (P/E) ratio is a valuation metric that compares a company's current share price to its per-share earnings. It is used to determine if a stock is overvalued or undervalued relative to its profits.

Altimmune Inc shows a P/E ratio of **-2.15**.

For valuation discipline, StockValueFinder prefers a P/E of 15 or lower. It is important to note that when a P/E ratio is negative, it typically indicates that the company is currently reporting a net loss rather than a profit. In this specific instance, while the P/E test was marked as **PASSED** by the system's specific logic, a negative P/E remains a signal of a non-profitable state.

**Educational Example:** If Company X has a P/E of 8, you are paying $8 for every $1 of profit. If Company Y has a P/E of 40, you are paying $40 for every $1 of profit. Assuming the business quality is sound, a P/E of 8 is more "value-oriented" because you are paying less for the earnings being generated.

Moving Average Trend and Entry Timing

The moving average signal is a technical indicator used to identify the direction of a stock's price trend. It helps investors understand momentum and provides a layer of timing discipline to avoid "catching a falling knife."

The current moving average signal for Altimmune Inc is **SELL / AVOID TREND**. Additionally, the entry signal is listed as **N/A**.

It is vital to understand that a "Sell" or "Avoid" trend signal is used for timing discipline; it is not a fundamental proof that the stock must rise or fall. It simply indicates that the current price trajectory is downward according to mathematical averages.

**Educational Example:** Think of a moving average like the slope of a hill. If you are walking down a steep hill (a Sell/Avoid trend), the direction of your movement is currently downward. An investor uses this to decide whether they want to enter a position now or wait for the "slope" to flatten out or turn upward.

Regarding entry and risk management

These fields are intended to provide educational reference levels for where an investor might theoretically look for entries or exits. When they are "N/A," it means the system has not identified specific technical zones for this ticker. These are never buy or sell orders, but tools for learning how to manage risk.

Overall Financial Strengths and Weaknesses

Based on the data provided, Altimmune Inc presents a complex financial profile

**Strengths:** - The company has passed the debt payback test, suggesting a specific mathematical relationship between its debt and cash/assets that meets the system's criteria. - The P/E valuation test was marked as passed by the system logic.

**Weaknesses:** - **Profitability:** The company failed the EPS strength test and has a negative ROIC of -33.81%, indicating it is currently losing capital. - **Solvency:** The company failed the interest coverage test, suggesting potential difficulty in servicing debt obligations from current earnings. - **Trend:** The moving average signal is in a "Sell/Avoid" trend, indicating negative momentum.

Risks and Limitations

Investing in biotechnology companies like Altimmune Inc involves significant uncertainty. The lack of positive EPS and a negative ROIC highlights the inherent risk in companies that are still in the capital-consumption phase. Investors must be aware of "purchasing-power risk"—the risk that inflation and economic shifts will erode the value of capital held in non-productive assets—and "long-term investment uncertainty" caused by the unpredictable nature of biotech clinical successes.

Furthermore, this analysis is limited to the specific numbers supplied. It does not account for future regulatory approvals, changes in government debt policy that might affect interest rates, or sudden shifts in the healthcare sector.

Educational Conclusion

Through this review of Altimmune Inc (ALT), we have seen how a multi-factor approach can paint a clearer picture of a company's health. While the stock price is $2.17, the underlying metrics—specifically the negative ROIC and failed interest coverage—contribute to a low StockValueFinder score of 33% and an **AVOID** rating.

By learning to identify these patterns—such as looking for ROIC above 10%, interest coverage above 6, and consistent EPS—investors can develop a disciplined framework for evaluating whether a company is building value or consuming it.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings